Verified against primary sources
Seven pages, 105 compounds, every number pulled from PubMed and ClinicalTrials.gov with the query declared.
What sets these pages apart from the rest of the site
Most of this site is an organized translation of a commercial secondary source. It is declared on every page, and it is the structural weakness of the material: if the source got it wrong, I repeat the error.
As páginas listadas abaixo são diferentes. Cada número nelas foi levantado por mim diretamente no PubMed e no ClinicalTrials.gov, com a consulta usada declarada dentro da própria página, para que qualquer pessoa possa repetir e me contradizer. Cobrem 176 compostos distintos, mais 106 substâncias e tratamentos levantados na rodada de 12 de setembro de 2026, nas nove páginas abertas naquele dia.
This is not a featured section out of methodological vanity. It is because, of the two things a site like this can do — list a dose or say what the dose is worth —, only the second is hard to find in Portuguese.
As páginas desta seção
| Page | Compounds | The central finding |
|---|---|---|
| The GLP-1s against the package insert | 6 | The only page on this site checked against an official answer key. The titration ladders match the FDA, step by step. The black box warning was missing, the 7.2 mg dose that exists only in Brazil was missing. |
| Mazdutide | 1 | The compound with the most mature evidence on the whole site, and the opposite of the pattern here: 12 phase 3 trials, with GLORY-1 in NEJM, GLORY-2 in JAMA and the two DREAMS in Nature — and no FDA registration. All 12 have Chinese sponsors and populations, and the meta-analysis pooling 2,292 participants rates the certainty in obesity as very low in the same text in which it reports double-digit weight loss |
| Exossomos | 1 | A assimetria mais extrema do site: 45.674 artigos no PubMed e 83 ensaios randomizados, menos de 0,2%. Dos 378 registros no ClinicalTrials.gov, 142 são observacionais — medem exossomo como marcador, não tratam ninguém com ele. Abri os nove de fase 3: um é um estudo de PET/CT em câncer de próstata que entrou na busca por citar “exosome analysis”, e sete dos outros oito têm 135 participantes ou menos. A FDA diz desde 2019 que não existe exossomo aprovado, com carta de advertência nova em fevereiro de 2026 |
| Incretinas e amilinas de nova geração | 13 | — |
| O eixo do GH fora do frasco de peptídeo | 7 | — |
| Geroprotetores | 17 | 6 das 17 linhas não têm nenhum ensaio de fase 3 registrado, entre elas o klotho recombinante e a troca plasmática. A rapamicina tem 259 — e nenhum dos que abri é sobre envelhecimento. Os 2 ensaios de fase 3 de fisetina declaram inscrição de zero participantes |
| Fígado e lipídio | 13 | — |
| Calvície — o antigo e o que está chegando | 18 | A clascoterona está registrada no Brasil na classe anti-acne, não para cabelo. O PP405, que já circula como pó de pesquisa, tem 1 artigo no PubMed e 0 ensaios de fase 3; o VDPHL01 tem o oposto — 0 artigos e 3 ensaios de fase 3 com mais de mil pessoas recrutadas |
| Reparo além do BPC e do TB-500 | 5 | A fase 3 da timosina β-4 é colírio para olho seco — 700 e 601 participantes, e não reparo de tendão. O AHK-Cu tem 1 artigo no PubMed. O único registro de fase 3 que a busca por polidesoxirribonucleotídeo devolve é de defibrotida em doença veno-oclusiva hepática |
| Neuro e cognição — o bloco russo e o que tem bula | 13 | — |
| Músculo, osso, eixo HPG e imune | 15 | — |
| Tratamentos que não são substância | 5 | O comparador que quase nunca aparece: a cirurgia bariátrica tem 36.916 artigos e 2.039 estudos registrados. Já a oxigenoterapia hiperbárica cruzada com envelhecimento tem 1 ensaio de fase 3, com 30 participantes |
| SARMs | 16 | The field's only two phase 3 trials were never published — 651 patients that exist only as a table on ClinicalTrials.gov, one of them posted seven and a half years late. And before the molecule comes the merchandise: only 52% of products contained any SARM. Andarine, YK-11 and S-23: zero trials |
| Semax — the evidence | 1 | The Russian trials used 6,000 to 18,000 mcg/day; the community uses 250 to 1,000. The range in practice has never been tested. Zero trial registrations, and one of the four studies is negative |
| KLOW — the evidence | 4 | The blend still has no trial, but BPC-157, TB-500 and GHK-Cu entered clinical phase in 2026 — three Hudson Biotech studies recruiting. It is no longer only preclinical |
| Nootropics | 44 | 32 have a trial, 12 have none. Modafinil leads with 425; noopept has 115 articles and zero trials. Four counts were inflated and were redone |
| Effect size | 19 | The other half of the page above: what the trials found, not how many exist. Where there is an effect, it sits between SMD 0.2 and 0.4. Three popular compounds have a large negative trial — oxiracetam (n=500), Cerebrolysin (n=1779) and piracetam |
| Khavinson bioregulators | 11 | Zero registered trials on ClinicalTrials.gov. Eight of the eleven have no clinical trial article at all. Seven do not even have an indexed chemical sequence. All of the family's clinical literature is concentrated in two compounds |
| Thymalin | 1 | 293 articles and 13 trials — the outlier of the family. But zero trial registrations, and the study behind the entire longevity claim is signed by the inventor himself |
| Meldonium | 1 | 357 articles, 35 trials, 7 trial registrations. The finding that decides its use is not about efficacy: the urinary detection window reaches 117 days after six days of use |
| Eastern European drugs | 17 | 29 registered trials, several of them phase 3 — the opposite of the bioregulators. And a forgotten signal: calcium hopantenate has 47 cases and 11 deaths from encephalopathy reported since 1986 — with 7 randomized trials, several in children |
| Over-the-counter supplements | 43 | Trial count item by item, with dose, for all 43. Resveratrol has 391 trials and disappointed; glycine, alpha-GPC, butyrate, fisetin and magnesium L-threonate have between 2 and 5 each |
| Herbal medicines and nootropics | 18 | Fadogia agrestis: zero. No trial, no human study — I checked the three articles PubMed tags as human and none of them is. Lion's Mane has two |
| Prescription-only items | 12 | Prescription drugs that appeared mixed in with vitamin D and creatine on a supplement list. The only page on the site without dosing, by decision |
Three things this survey taught
1. A lot of literature is not the same as evidence
The eleven Khavinson bioregulators add up to nearly two hundred articles on PubMed and zero registered trials. Prior registration is what keeps a bad outcome from turning into a different outcome at publication — without it, there is no way to know how many studies stayed in the drawer. Article count measures academic activity, not reliability.
2. High volume is not a favorable result
Resveratrol has 391 randomized trials and meta-analyses, and the promise did not hold up. Ginkgo has 88 and is still not recommended for preventing dementia, because the large trials came back negative. Probiotics have 5,248 — the highest number on the site — and are the most misleading, because the effect is strain-specific and does not transfer to the bottle you bought.
3. Searching by brand name inflates the count
While surveying the bioregulators, a randomized trial turned up for Ovagen. I went to read it: it was a superovulation study in cows, because Ovagen is also a brand of veterinary FSH. In the Eastern Europe block, cocarboxylase and cytochrome C show up with hundreds of articles about the biochemistry of metabolism and apoptosis — not about the injectable. When the molecule has a biological function of its own, the count measures the biology, not the drug.
On the nootropics page the same problem showed up in another form: PubMed expands the search for armodafinil to the MeSH term modafinil, and returns 2,437 versus 2,411 — almost the same set. Restricted to title and abstract, armodafinil has 260. And four supplement counts were inflated for the same reason: L-tyrosine dropped from 199 to 14, uridine from 62 to 6, forskolin from 30 to 5, and agmatine from 9 to zero.
What is still missing
- I read abstracts and metadata, not full articles, except where the finding depended on it — Fadogia and calcium hopantenate, which I opened and checked one by one.
- Count is not quality. A high number can be a hundred small, poorly done trials. It is the central limitation of the method used here.
- There are no more items without a count. The 27 that were blank on the supplements, herbal medicines and Eastern Europe pages have been closed, and the two on the KLOW page as well. Closing them corrected a wrong number of mine — Cortexin had 26 articles declared and has 127 — and showed that cocarboxylase, cytochrome C and Ethoxidol have no randomized trial at all.
- Russian literature outside PubMed was not consulted. The Khavinson school publishes heavily in non-indexed journals — absence here does not prove absolute absence.
- As outras 57 páginas do site continuam dependendo da fonte secundária. Este método ainda não foi aplicado a elas.